Luspatercept Achieves Clinically Meaningful Outcomes in Lower-Risk MDS | Blood Cancers Today
Luspatercept treatment facilitated hemoglobin levels of 10 g/dL or higher and reduced transfusion dependency in patients with lower-risk myelodysplastic syndromes.